Bispecific antibodies have demonstrated high efficacy in the treatment of Refractory/relapsed b-cell non-Hodgkin lymphomas. However, a non-negligible percentage of patients do not respond to therapy and/or develop significant treatment toxicity.
Age≥18 years
Patients with histologically documented non-Hodgkin B lymphoma, with relapsed/refractory disease and candidates for BsAbs therapy (glofitamab, epcoritamab, mosunetuzumab) according to clinical indication and AIFA reimbursement criteria
obtaining signed and dated informed consent before the start of any screening or study-specific procedure
Evidence of concomitant and uncontrolled diseases that could affect protocol compliance or interpretation of results.
Concomitant secondary neoplasm.